Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases
Open Access
- 1 December 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (12) , 5977-5986
Abstract
The type II topoisomerases DNA gyrase (GyrA/GyrB) and topoisomerase IV (ParC/ParE) are well-validated targets for antibacterial drug discovery. Because of their structural and functional homology, these enzymes are amenable to dual targeting by a single ligand. In this study, two novel benzothiazole ethyl urea-based small molecules, designated compound A and compound B, were evaluated for their biochemical, antibacterial, and pharmacokinetic properties. The two compounds inhibited the ATPase activity of GyrB and ParE with 50% inhibitory concentrations of 90 s against clinical isolates ranged from 0.015 μg/ml for Streptococcus pneumoniae to 0.25 μg/ml for Staphylococcus aureus . No cross-resistance with common drug resistance phenotypes was observed. In addition, no synergistic or antagonistic interactions between compound A or compound B and other antibiotics, including the topoisomerase inhibitors novobiocin and levofloxacin, were detected in checkerboard experiments. The frequencies of spontaneous resistance for S. aureus were −10 with compound A and −11 with compound B at concentrations equivalent to 8× the MICs. These values indicate a multitargeting mechanism of action. The pharmacokinetic properties of both compounds were profiled in rats. Following intravenous administration, compound B showed approximately 3-fold improvement over compound A in terms of both clearance and the area under the concentration-time curve. The measured oral bioavailability of compound B was 47.7%.Keywords
This publication has 45 references indexed in Scilit:
- Tackling antibiotic resistanceNature Reviews Microbiology, 2011
- Exploiting bacterial DNA gyrase as a drug target: current state and perspectivesApplied Microbiology and Biotechnology, 2011
- Challenges of Antibacterial DiscoveryClinical Microbiology Reviews, 2011
- 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IVBioorganic & Medicinal Chemistry Letters, 2009
- Antibiotics for Emerging PathogensScience, 2009
- Multidrug Resistance in BacteriaAnnual Review of Biochemistry, 2009
- The assembled structure of a complete tripartite bacterial multidrug efflux pumpProceedings of the National Academy of Sciences, 2009
- Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity RelationshipsJournal of Medicinal Chemistry, 2008
- Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial CompoundsAntimicrobial Agents and Chemotherapy, 2007
- In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole ClassAntimicrobial Agents and Chemotherapy, 2006